《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

doi:10.16139/j.1007-9610.2024.05.07

外科理论与实践 ›› 2024, Vol. 29 ›› Issue (05): 405-408.doi: 10.16139/j.1007-9610.2024.05.07

《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

陆裕杰, 朱思吉()

上海交通大学医学院附属瑞金医院普外科乳腺疾病诊治中心，上海 200025

收稿日期:2024-08-12 出版日期:2024-09-25 发布日期:2025-01-23
通讯作者: 朱思吉，E-mail: zsj_mu@yeah.net
基金资助:
上海交通大学“交大之星”计划医工交叉研究基金(YG2024QNB05)

The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

LU Yujie, ZHU Siji()

Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2024-08-12 Online:2024-09-25 Published:2025-01-23

摘要/Abstract

摘要：

骨调节剂(BMA)目前主要包括双膦酸盐(BP)和地舒单抗，可减少乳腺癌肿瘤骨转移引起的骨相关事件。Journal of Clinical Oncology于2022年1月在线刊发了2022版《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》。新版指南提示应与所有有指征接受术后辅助治疗的绝经后早期乳腺癌病人，讨论BP辅助治疗。唑来膦酸、氯膦酸盐、伊班膦酸均为推荐药物，建议BP持续时长为2~3年。ABCSG-18与D-CARE研究的结果不一致，且缺乏直接比较地舒单抗与BP作为早期乳腺癌辅助治疗的研究数据，因此不建议使用地舒单抗用于辅助治疗。总之，BP在早期乳腺癌辅助治疗中的地位被进一步肯定，而地舒单抗的价值仍未明确。

关键词: 乳腺癌, 骨调节剂, 双膦酸盐, 辅助治疗

Abstract:

Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.

Key words: Breast cancer, Bone-modifying agent(BMA), Bisphosphonates(BP), Adjuvant treatment

中图分类号:

R737.9

陆裕杰, 朱思吉. 《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读[J]. 外科理论与实践, 2024, 29(05): 405-408.

LU Yujie, ZHU Siji. The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 405-408.

参考文献 9

[1]	中国医师协会肿瘤医师分会乳腺癌学组, 中国抗癌协会国际医疗交流分会. 骨改良药物安全性管理专家共识[J]. 中华肿瘤杂志, 2021, 43(6):622-628.
	Breast Cancer Group, Chinese Medical Doctor Association, International Medical Society, Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents[J]. Chin J Oncol, 2021, 43(6):622-628.
[2]	DHESY-THIND S, FLETCHER G G, BLANCHETTE P S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:a cancer care ontario and American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(18):2062-2081.
[3]	GNANT M, PFEILER G, STEGER G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18):disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):339-351.
[4]	COLEMAN R, FINKELSTEIN D M, BARRIOS C, et al. Adjuvant denosumab in early breast cancer (D-CARE):an international, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):60-72.
[5]	GRALOW J R, BARLOW W E, PATERSON A H G, et al. Phase Ⅲ randomized trial of bisphosphonates as adjuvant therapy in breast cancer:S0307[J]. J Natl Cancer Inst, 2020, 112(7):698-707.
[6]	FRIEDL T W P, FEHM T, MÜLLER V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(8):1149-1157.
[7]	EISEN A, SOMERFIELD M R, ACCORDINO M K, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:ASCO-OH (CCO) guideline update[J]. J Clin Oncol, 2022, 40(7):787-800.
[8]	Predict Breast:NHS PREDICT Tool[EB/OL]. [2024-08-12]. https://breast.predict.nhs.uk/.
[9]	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer:meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001):1353-1361.

[1]	曹卫刚, 杨振林. 自体皮瓣重建乳腺癌术后胸壁缺损的临床经验[J]. 组织工程与重建外科杂志, 2025, 21(3): 225-.
[2]	杨清玉, 曾媛媛, 王秋舟, 等. 互助支持干预对乳腺癌改良根治术后假体重建患者家庭关怀及社会支持水平的影响[J]. 组织工程与重建外科杂志, 2025, 21(3): 283-.
[3]	乐森, 左越, 邓正栋, 王剑明. 延迟诊断的胆囊癌手术治疗的争议焦点[J]. 外科理论与实践, 2025, 30(2): 106-111.
[4]	周晓萍　狄美华　何敏敏. 股深动脉穿支（PAP）皮瓣乳房再造术的围手术期护理[J]. 组织工程与重建外科杂志, 2025, 21(2): 134-.
[5]	黄相, 张天怡, 宋达疆, 等. 制备保留外侧腹直肌的带蒂横行腹直肌皮瓣的策略和技术要点[J]. 组织工程与重建外科杂志, 2025, 21(2): 113-.
[6]	金小丁综述, 邹强, 金贻婷审校. 保乳手术术中切缘评估技术的现状与进展[J]. 外科理论与实践, 2025, 30(2): 176-182.
[7]	徐旺旺1,2，许良凤1,2，刘宁徽3，律娜3. 基于多注意力卷积神经网络的乳腺癌组织学图像诊断[J]. J Shanghai Jiaotong Univ Sci, 2025, 30(1): 91-106.
[8]	宋达疆, 张天怡, 王志远, 等. 分叶游离下腹部皮瓣移植乳房再造的血管吻合方式选择 [J]. 组织工程与重建外科杂志, 2024, 20(4): 428-.
[9]	郝昆, 孙宇光, 王仁贵, 等. 抽吸减容术治疗乳腺癌术后上肢淋巴水肿[J]. 组织工程与重建外科杂志, 2024, 20(1): 69-.
[10]	童一苇, 陈小松. 抗体药物偶联物在晚期三阴性乳腺癌治疗中的研究进展[J]. 外科理论与实践, 2024, 29(06): 533-536.
[11]	阮淼, 笪倩, 许海敏, 董磊, 费晓春. HER2低表达乳腺癌临床病理学特征及预后研究[J]. 诊断学理论与实践, 2024, 23(05): 500-508.
[12]	赵鑫, 高鹏, 陈洁. 机器人辅助手术系统在乳腺癌治疗中的应用及前景[J]. 外科理论与实践, 2024, 29(05): 376-381.
[13]	曹希, 骆勇超, 沈松杰. 适合中国女性的乳腺癌筛查策略[J]. 外科理论与实践, 2024, 29(05): 382-388.
[14]	笪倩, 阮淼, 费晓春, 王朝夫. 人工智能在乳腺癌病理诊断中的应用及研究展望[J]. 外科理论与实践, 2024, 29(05): 389-395.
[15]	周驿航, 曾子威, 康亮. 直肠癌治疗器官保留策略：馅饼还是陷阱?[J]. 外科理论与实践, 2024, 29(05): 396-400.

《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 9

相关文章 15

编辑推荐

Metrics

本文评价